M2D2 at UMass Lowell United States

The Massachusetts Medical Device Development Center (M2D2) is a lifeline for the state’s smaller medical device companies, offering inventors and executives easy, affordable, and coordinated access to world-class researchers and resources at the Lowell and Worcester campuses of the University of Massachusetts.

Learn more.

Mary Ann Picard
Associate Director 

Maddon Advisors LLC United States

Mr Paul Maddon
Founder 

Madison County Economic Development Authority - Mississippi Bio-Medical Business Collaboratory United States

The Madison County Economic Development Authority, or MCEDA as we are known locally, offers a broad array of economic development, business development, and corporate site location assistance services to new and expanding businesses and industry. 

MCEDA owns the newly created Mississippi Bio-Medical Business Collaboratory. A 60,000 square foot office and educational services facility for bio-medical and medical related companies. We are seeking new tenants for the facility. Current tenants include: TeleHealthOne (telemedicine provider), Xerox, Mississippi Association of Nurse Practitioners, and the Global Training Institute (a brand new state-of-the art Surgical and Medical Simulation Center).

Mr Tim Coursey
Executive Director 
Ms Danielle Winningham
Business Development Manager 

Marie Landel Associates United States

Mrs Alexandra Suhas
CEO 
Marie Landel
CEO 

Masonic Medical Research Laboratory United States

Masonic Medical Research Laboratory is a not-for-profit institute dedicated to improving the health and quality of life for all. The Laboratory's primary mission is to conduct high quality basic and clinical research aimed at generating knowledge and information necessary for development of medical cures and treatments of tomorrow. The Laboratory is also committed to providing education and training to basic scientists, clinical researchers and students who will perpetuate and extend the fight against disease.

Specialties

The Laboratory's primary focus is on basic medical research in the fields of Experimental Cardiology, Cardiac Electrophysiology, Molecular Biology and Molecular Genetics.

Dr John Story,Jr
Director of Administration 
Dr Hector Barajas-Martinez
Clinical Director of Molecular Genetics 
Dr Matthew Betzenhauser
Acting Director of Research 

Mass Innovation Labs United States

ass Innovation Labs embodies an ecosystem of innovators in its 124,000 square foot first-class chemistry and biology space in the heart of Kendall Square. We provide comprehensive solutions for growing companies, including animal facilities, co-located CRO services and operational needs. Our goal is to reduce the time for teams to overcome hurdles on their way to a milestone. Our space offers a collaborative ecosystem that allows a company to run as a lean organization and focus on the science with expert drug development partners down the hall. 

At Milabs, our full service offerings allow you to innovate like a start up while commercializing like a pharma. 

Call us to schedule a visit!

Specialties

R&D ACCELERATION IN A COLLABORATIVE ECOSYSTEM, TOP QUALITY RESEARCH SPACES AND RESOURCES, FACILITATE BIOTECH OPPORTUNITIES, IN-HOUSE MANAGEMENT SERVICES AND EXPERTISE

Seth Taylor
CFO 

Massat Consulting Group United States

Certified Public Accountants

“We are above all a human size company built by men and women used to make decisions on a daily basis without having to refer for authorization to a heavy hierarchy” (Serge J. Massat, 2001).

At Massat Consulting Group we focus on the International client with subsidiaries abroad. We serve as a link and interface between the parent company and its subsidiaries.

Our Partners and Managers are Certified Public Accountant (CPA) in the USA but also “Expert Comptables” in France , “Contadores Publicos” in Mexico and Chartered Accountant in the United Kingdom.

Our team speak English, French and Spanish.

Website:
www.mcgintl.com
Mr Andrew Massat
Mr Andrew Massat
Partner 

MD Anderson Cancer Center United States

MEBIAS United States

MEBIAS holds a game-changing platform to discover next generation, pathway-selective GPCR drugs devoid of on-target side effects once thought to be unavoidable.

Summary

Assets

  • Fully validated in vitro and ex vivo assay suite correlating ligand-induced dynamic conformation of GPCR to pathway-specific signaling

  • Differentiated mu-opioid receptor pre-development candidates for the treatment of pain, plus backup molecules

Business Proposal

MEBIAS seeks capital to establish a NewCo:

  • To co-develop our mu-opioid drug candidate

  • To fund lead discovery of additional targets

Team

Shariff Bayoumy – Unique expertise in GPCR expression and purification; former head of Janssen gene‑to‑protein team on soluble and membrane proteins

Lawrence Kuo – Former head, Structural Biology (Janssen); former head, Enzymology and Structural Biology (Merck); core member of project teams for Crixivan™ and Stocrin™

Brett A. Tounge – Extensive expertise in designing drug like small molecules from hit discovery through NME declaration; former head of Janssen NMR team

Customer Problem

G-protein coupled receptor (GPCR) therapeutics exhibit significant on-target adverse effects that can be alleviated by developing pathway-selective/biased drugs. The clinical benefit to dial pathway selectivity into future GPCR drugs has been clearly established, but current discovery approaches in the pharma/biotech industry are inadequate to speedily design and develop biased drugs.

Target Market

With the downsizing of internal R&D in the pharma industry, there is a dire need for new discovery platforms and assets to help fill early pipelines. GPCR therapeutics comprise ~30% of current prescribed drugs with a global market of >USD100 billion and a projected growth of 20% by 2018.

Customer

Our immediate targeted customers will be pharma and biotech R&D. Our intention is to co-develop GPCR pathway-selective drugs to treat CNS, Metabolic, and Inflammatory related disorders. The pathway-selective GPCR landscape is wide open.

Business Model

The first round of funding from investors will be used to form a NewCo with the specific goal to discover and progress pre-development candidates for pathway-selective GPCR indications. In hand we hold differentiated mu-opioid receptor pre-development candidates for the treatment of pain. Revenues from the sale or partnering of our pre-clinical assets will fund new R&D efforts.

Competitive Advantage

Additional players in the GPCR pathway selectivity space are highly desirable to help advance clinical need in numerous disease areas. Given our experience and access to two key technologies – native GPCR purification and protein nuclear magnetic resonance – our approach offers unique advantages lacking in current methodologies (that employ only cell-based assays).  We have demonstrated our competitive advantage by successfully delivering a series of mu‑opioid receptor compounds among which is an NME-stage compound.

Dr LAWRENCE KUO
Senior Director 
Dr Brett Tounge
Associate Director 
Mr Shariff Bayoumy

MEDIAN Technologies France

MEDIAN Technologies MEDIAN Technologies provides advanced software solutions, medical expertise and services for interpretation and management of images in oncology. Industry sectors Medtech Therapeutics Area Oncology
Your innovative solution

Our technology helps automate/standardize image interpretation ; it also enables quantification of standard imaging criteria and advanced imaging biomarkers, to provide early proof of treatment response. Our Lesion Management Solutions (LMS) platform is a proprietary suite of software modules for automated/semi-automated detection, quantitative measurement and follow-up of tumors. 

Which problem are you solving ?

MEDIAN's technology solves frequently observed issues in image interpretation such as intra- and inter-reader variability of measurement or lack of standardization of reading/interpretation processes. Both variability and insufficient level of standardization lead to a decrease of imaging data reliability, which can, for instance impact the statistical power of data in clinical trials. 

Target market segments

Oncology drug development -clinical trials (phases I to phases III) / Novel biomarkers development in oncology and other therapeutic areas / Imaging based cancer screening programs

Key value proposition

Quantitative and standardized data analysis supported by cutting edge, FDA approved, technology / Expertise in advanced imaging biomarkers for more accurate evaluation of drug efficacy / Real time, streamlined image workflow for clinical trials

Jerome WINDSOR
VP Business development